Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

120 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Tissue-resident memory CAR T cells with stem-like characteristics display enhanced efficacy against solid and liquid tumors.
Jung IY, Noguera-Ortega E, Bartoszek R, Collins SM, Williams E, Davis M, Jadlowsky JK, Plesa G, Siegel DL, Chew A, Levine BL, Berger SL, Moon EK, Albelda SM, Fraietta JA. Jung IY, et al. Among authors: siegel dl. Cell Rep Med. 2023 Jun 20;4(6):101053. doi: 10.1016/j.xcrm.2023.101053. Epub 2023 May 23. Cell Rep Med. 2023. PMID: 37224816 Free PMC article.
Advanced glycation end products on stored red blood cells increase endothelial reactive oxygen species generation through interaction with receptor for advanced glycation end products.
Mangalmurti NS, Chatterjee S, Cheng G, Andersen E, Mohammed A, Siegel DL, Schmidt AM, Albelda SM, Lee JS. Mangalmurti NS, et al. Among authors: siegel dl. Transfusion. 2010 Nov;50(11):2353-61. doi: 10.1111/j.1537-2995.2010.02689.x. Transfusion. 2010. PMID: 20492604 Free PMC article.
The receptor for advanced glycation end products mediates lung endothelial activation by RBCs.
Mangalmurti NS, Friedman JL, Wang LC, Stolz D, Muthukumaran G, Siegel DL, Schmidt AM, Lee JS, Albelda SM. Mangalmurti NS, et al. Among authors: siegel dl. Am J Physiol Lung Cell Mol Physiol. 2013 Feb 15;304(4):L250-63. doi: 10.1152/ajplung.00278.2012. Epub 2012 Dec 28. Am J Physiol Lung Cell Mol Physiol. 2013. PMID: 23275625 Free PMC article.
NY-ESO-1-specific TCR-engineered T cells mediate sustained antigen-specific antitumor effects in myeloma.
Rapoport AP, Stadtmauer EA, Binder-Scholl GK, Goloubeva O, Vogl DT, Lacey SF, Badros AZ, Garfall A, Weiss B, Finklestein J, Kulikovskaya I, Sinha SK, Kronsberg S, Gupta M, Bond S, Melchiori L, Brewer JE, Bennett AD, Gerry AB, Pumphrey NJ, Williams D, Tayton-Martin HK, Ribeiro L, Holdich T, Yanovich S, Hardy N, Yared J, Kerr N, Philip S, Westphal S, Siegel DL, Levine BL, Jakobsen BK, Kalos M, June CH. Rapoport AP, et al. Among authors: siegel dl. Nat Med. 2015 Aug;21(8):914-921. doi: 10.1038/nm.3910. Epub 2015 Jul 20. Nat Med. 2015. PMID: 26193344 Free PMC article.
Anti-CD19 CAR T cells with high-dose melphalan and autologous stem cell transplantation for refractory multiple myeloma.
Garfall AL, Stadtmauer EA, Hwang WT, Lacey SF, Melenhorst JJ, Krevvata M, Carroll MP, Matsui WH, Wang Q, Dhodapkar MV, Dhodapkar K, Das R, Vogl DT, Weiss BM, Cohen AD, Mangan PA, Ayers EC, Nunez-Cruz S, Kulikovskaya I, Davis MM, Lamontagne A, Dengel K, Kerr ND, Young RM, Siegel DL, Levine BL, Milone MC, Maus MV, June CH. Garfall AL, et al. Among authors: siegel dl. JCI Insight. 2018 Apr 19;3(8):e120505. doi: 10.1172/jci.insight.120505. eCollection 2018 Apr 19. JCI Insight. 2018. PMID: 29669947 Free PMC article. Clinical Trial.
Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemia.
Fraietta JA, Lacey SF, Orlando EJ, Pruteanu-Malinici I, Gohil M, Lundh S, Boesteanu AC, Wang Y, O'Connor RS, Hwang WT, Pequignot E, Ambrose DE, Zhang C, Wilcox N, Bedoya F, Dorfmeier C, Chen F, Tian L, Parakandi H, Gupta M, Young RM, Johnson FB, Kulikovskaya I, Liu L, Xu J, Kassim SH, Davis MM, Levine BL, Frey NV, Siegel DL, Huang AC, Wherry EJ, Bitter H, Brogdon JL, Porter DL, June CH, Melenhorst JJ. Fraietta JA, et al. Among authors: siegel dl. Nat Med. 2018 May;24(5):563-571. doi: 10.1038/s41591-018-0010-1. Epub 2018 Apr 30. Nat Med. 2018. PMID: 29713085 Free PMC article.
B cell maturation antigen-specific CAR T cells are clinically active in multiple myeloma.
Cohen AD, Garfall AL, Stadtmauer EA, Melenhorst JJ, Lacey SF, Lancaster E, Vogl DT, Weiss BM, Dengel K, Nelson A, Plesa G, Chen F, Davis MM, Hwang WT, Young RM, Brogdon JL, Isaacs R, Pruteanu-Malinici I, Siegel DL, Levine BL, June CH, Milone MC. Cohen AD, et al. Among authors: siegel dl. J Clin Invest. 2019 Mar 21;129(6):2210-2221. doi: 10.1172/JCI126397. J Clin Invest. 2019. PMID: 30896447 Free PMC article. Clinical Trial.
CAR T cell viability release testing and clinical outcomes: is there a lower limit?
Chong EA, Levine BL, Grupp SA, Davis MM, Siegel DL, Maude SL, Gladney WL, Frey NV, Porter DL, Hwang WT, Chong ER, June CH, Schuster SJ. Chong EA, et al. Among authors: siegel dl. Blood. 2019 Nov 21;134(21):1873-1875. doi: 10.1182/blood.2019002258. Blood. 2019. PMID: 31554634 Free PMC article. No abstract available.
CD19-targeting CAR T cell immunotherapy outcomes correlate with genomic modification by vector integration.
Nobles CL, Sherrill-Mix S, Everett JK, Reddy S, Fraietta JA, Porter DL, Frey N, Gill SI, Grupp SA, Maude SL, Siegel DL, Levine BL, June CH, Lacey SF, Melenhorst JJ, Bushman FD. Nobles CL, et al. Among authors: siegel dl. J Clin Invest. 2020 Feb 3;130(2):673-685. doi: 10.1172/JCI130144. J Clin Invest. 2020. PMID: 31845905 Free PMC article. Clinical Trial.
120 results